公司資料
Autolus Therapeutics plc 股價、新聞與催化劑
- 股票代碼:
- AUTL
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United Kingdom
股票表現
2.28 USD (+6.05%)
收盤價
最後更新: 2026年8月17日
466M USD
市值
股價為何變動
As of Aug 17, 2026, AUTL closed up 6.05% at $2.28. No new same-company headline was identified in the current news window.
公司概覽
Programmable T-Cell Therapy Company
Autolus Therapeutics develops, manufactures, and commercializes next-generation T-cell therapies for cancer and autoimmune disease using modular cell-programming technologies.
AUCATZYL
AUCATZYL, or obecabtagene autoleucel, is an autologous CD19 CAR T-cell therapy commercialized for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Fast Off-Rate CAR Design
Obe-cel uses a fast off-rate CD19 binding domain intended to reduce excessive T-cell activation while preserving antitumor activity and persistence.
Integrated Manufacturing
Autolus controls manufacturing and product delivery, supporting launches in the United States and United Kingdom and providing infrastructure for additional cell-therapy programs.
Pipeline Expansion
The company is extending its T-cell platform into additional hematologic cancers and autoimmune disease while building on physician experience with obe-cel.
未來催化劑
- Autolus’s next catalyst is AUCATZYL commercial launch execution and any follow-on CAR-T update that proves the franchise can scale. The market is watching whether the cell-therapy rollout can translate into durable adoption.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。